Press Releases

 
Press Releases
Date Title and Summary View
Jul 29, 2015 Zuplenz is indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV)Novel, oral soluble film technology provides convenient delivery and key patient benefits PORTLAND, Ore., July 29, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, In...
Jul 28, 2015 PORTLAND, Ore., July 28, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that the Company will report its second quarter 2015 financial results on Th...
Jun 15, 2015 GALE-401 was well tolerated with primarily Grade 1 and 2 toxicitiesPhase 2 pilot study demonstrated an Overall Response Rate of 78% PORTLAND, Ore., June 15, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medic...
May 28, 2015 PORTLAND, Ore., May 28, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer wil...
May 27, 2015 GALE-301 demonstrates promising preliminary efficacy data with a projected 78% reduction in relative risk of recurrence in the 1000 mcg dose cohort Leica Biosystem's Bond Oracle HER2 Immunohistochemistry (IHC) System distinguishes HER2 1+ and 2+ expressions and supports its use as a companion diagnostic for NeuVax™ (nelipepimut-S) PO...
May 22, 2015 PORTLAND, Ore., May 22, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's Phase 2 clinical trial of GALE-401, or Ana...
May 7, 2015 Completed enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial Commercial programs continue on trackAbstral® (fentanyl) Sublingual Tablets achieve net revenue of $2.8 million; full year 2015 net revenue guidance reiterated at $15-$18 millionZuplenz® (ondansetron) Oral Soluble Film product launch targeted for...
Apr 23, 2015 PORTLAND, Ore., April 23, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that the Company will report its first quarter 2015 financial results on Th...
Apr 14, 2015 PORTLAND, Ore., April 14, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the completion of enrollment in the NeuVax™ (nelipepimut-S) Pha...
Apr 10, 2015 PORTLAND, Ore., April 10, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the closing of the exercise of the underwriters' option to purchase a...
Page:
1
... NextLast
= add release to Briefcase